TU 2100

Drug Profile

TU 2100

Latest Information Update: 03 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tamarkin Pharmaceutical Innovation
  • Class Antipsoriatics; Drug conjugates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acne; Hair disorders; Psoriasis; Seborrhoeic dermatitis

Most Recent Events

  • 25 Aug 2004 This compound is still in active development
  • 28 Feb 2003 Phase-II clinical trials in Hair disorders (Topical)
  • 28 Feb 2003 Phase-II clinical trials in Psoriasis (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top